Hunting a T-cell cure for solid tumors, Rick Klausner’s Lyell steers to Nasdaq — with big dreams and fresh fortunes on the line
In the 3 years since ex-NCI chief Rick Klausner founded Lyell, he’s raised hundreds of millions of dollars, recruited some of the top scientists in the field of cell therapy 2.0 and allied himself with an array of big and small explorers involved in the quest of mastering cell exhaustion and durability.
Tuesday, though, was a time for throwing some dice on Nasdaq, and waiting to see how fortunes could be divvied up in the IPO to come.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.